サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758075

チェックポイント阻害薬不応性がんの世界市場

Checkpoint Inhibitor Refractory Cancer

出版日
ページ情報
英文 287 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
チェックポイント阻害薬不応性がんの世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 287 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

チェックポイント阻害薬不応性がんの世界市場、2030年には米国で488億米ドルに達する見込み

2024年に315億米ドルと推定されたチェックポイント阻害薬不応性がんの世界市場は、2024～2030年の分析期間にCAGR 7.6%で成長し、2030年には488億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるPD-1阻害剤タイプは、CAGR 8.8%を記録し、分析期間終了までに330億米ドルに達すると予測されます。PD-L1阻害剤タイプの成長率は、分析期間中CAGR 5.0%と推定されます。

米国市場は86億米ドルと推定、中国はCAGR 12.0％で成長予測

米国のチェックポイント阻害薬不応性がん市場は、2024年に86億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに105億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.7%と7.3%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界のチェックポイント阻害薬不応性がん市場- 主要動向と促進要因のまとめ

なぜチェックポイント阻害薬への不応性ががん治療の新たなフロンティアとして台頭しているのか？

チェックポイント阻害剤は、腫瘍を攻撃する免疫系を解き放つことにより、がん治療に革命をもたらしたが、患者のかなりの割合が、限られた、あるいは全く反応を示さない、チェックポイント阻害剤不応性がんと呼ばれる複雑な状況に陥っています。このようながんは、免疫チェックポイント阻害療法に最初に反応しないか（原発性抵抗性）、あるいは反応した後に進行する（獲得抵抗性）がんです。この課題は、メラノーマ、非小細胞肺がん（NSCLC）、腎細胞がん、トリプルネガティブ乳がんにおいて特に深刻であり、耐性率は腫瘍の種類やバイオマーカーの発現によって40％から60％以上と幅があります。不応性の根本的な原因を理解することは、腫瘍内科医、バイオ医薬品企業、研究者にとって同様に重要な優先事項となってきています。腫瘍微小環境動態、腫瘍変異負荷の低さ、T細胞浸潤の欠如（低温腫瘍）、免疫逃避機構はすべて、チェックポイントの有効性を低下させる役割を担っています。このような洞察は、治療開発を急速に再構築し、併用療法、新規免疫標的、個別化医療アプローチにおける革新を促しています。チェックポイント阻害薬単剤療法に代わる治療法に対する臨床的需要が高まる中、難治性がん領域は、臨床的な脚注から、進化する免疫腫瘍学の展望における中心的な焦点へと移り変わっています。

併用療法は難治性がんのブレークスルーとなり得るか？

併用療法は、チェックポイント阻害剤耐性を克服するための最も有効なアプローチと見なされつつあります。これには、チェックポイント阻害薬と化学療法、放射線療法、標的療法、あるいはオンコリティックウイルス、がんワクチン、T細胞作動薬などの免疫療法との組み合わせが含まれます。抗PD-1/PD-L1薬とイピリムマブなどのCTLA-4阻害薬を組み合わせた試験では、メラノーマやNSCLCの特定のサブタイプで奏効率の改善が示されています。新しい戦略では、LAG-3、TIGIT、TIM-3といった次世代のチェックポイント分子を標的とする薬剤を組み込んで、第一世代の薬剤の限界を回避しています。さらに、T細胞浸潤を増加させることにより、チェックポイント阻害薬に対してより感受性を高めることにより、"冷たい"腫瘍を"熱い"腫瘍に再プログラムするためのエピジェネティック・モジュレーターがテストされています。腫瘍の不均一性や免疫回避に対処するため、個別化新抗原ワクチンや、CAR-T細胞やTCR-T細胞を含む養子T細胞療法も開発中です。これらの戦略には毒性とコストに関する懸念があるが、現在進行中の臨床試験では、有効性と安全性を改善するために、投与レジメンとバイオマーカーに基づく患者選択を最適化しています。FDAとEMAは、有望なコンボ治療薬にブレークスルー指定とファストトラック承認を与えるようになってきており、この治療フロンティアの緊急性と可能性を強調しています。

治療戦略の形成において、診断とバイオマーカーはどのような役割を果たしているか？

チェックポイント阻害剤の不応性に対処するためには、精密腫瘍学が不可欠であり、コンパニオン診断とバイオマーカープロファイリングがその中心的役割を担っています。PD-L1発現、腫瘍変異負荷（TMB）、マイクロサテライト不安定性（MSI）の状態は基礎的な指標であるが、インターフェロン-ガンマシグネチャー、T細胞受容体クローナリティ、腸内マイクロバイオーム組成などの新しいバイオマーカーが人気を集めています。シングルセルRNAシーケンスやマルチプレックス免疫組織化学のような先端技術は、研究者が腫瘍内の免疫細胞ランドスケープを解読するのに役立っており、耐性パターンのより良い予測を可能にしています。循環腫瘍DNA（ctDNA）解析は、特に後天性耐性の観点から、微小残存病変や早期再発のモニタリングに不可欠なツールになりつつあります。さらに、リアルタイムでの意思決定や患者の層別化のために、マルチオミクスデータ（ゲノム、トランスクリプトーム、プロテオーム）を統合する人工知能が使用されつつあります。このような診断法は、新たな臨床試験の患者選択にも役立ち、募集の効率と試験成績を向上させています。個別化腫瘍学をサポートするために償還制度が進化するにつれ、コンパニオン診断薬の開発は医薬品承認と密接に結びついており、チェックポイント阻害薬不応性がん市場における成長エンジンとしての役割を確固たるものにしています。

何がチェックポイント阻害薬不応性がん治療薬市場の成長を牽引しているのか？

チェックポイント阻害薬不応性がん市場の成長は、技術の進歩、臨床ニーズ、精密ベースのヘルスケアモデルと密接に結びついたいくつかの要因によって牽引されています。第一に、免疫療法を受ける患者層の拡大は、当然ながら難治性症例の並行的な増加につながり、大きなアンメットニーズを生み出しています。次世代シークエンシングとリアルタイム分子診断の進歩により、耐性メカニズムをより正確に同定できるようになり、オーダーメイドの治療戦略が容易になりつつあります。製薬会社は、有望な臨床試験データと規制上の優遇措置に後押しされ、新規ターゲットと免疫腫瘍学パイプラインへの投資を加速させています。エンドユースの観点からは、三次がん治療センターや大学病院が先進的な免疫療法の組み合わせを率先して導入しており、また、がん専門ネットワークを通じて分散型のアクセスが改善されつつあります。消費者の行動もまた変化しています。患者や介護者は治療の選択肢を理解することに積極的になり、しばしば臨床試験や実験的治療を積極的に求めるようになっています。さらに、実臨床のエビデンスや患者登録の利用可能性が高まることで、長期的な治療反応や耐性動向に関する深い洞察が得られ、医薬品開発における反復的な革新が可能になりつつあります。チェックポイント阻害薬不応性がんに対する闘いにおいて、成長、革新、転帰の改善が促されるダイナミックなエコシステムが、これらの相互に関連する推進力によって構築されつつあります。

セグメント

タイプ（PD-1阻害剤タイプ、PD-L1阻害剤タイプ、その他のタイプ）、アプリケーション（肺がんアプリケーション、膀胱がんアプリケーション、メラノーマアプリケーション、ホジキンリンパ腫アプリケーション、その他のアプリケーション）

調査対象企業の例

  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celltrion
  • Genentech（Roche）
  • GlaxoSmithKline（GSK）
  • Hengrui Medicine
  • Incyte Corporation
  • Janssen Pharmaceuticals
  • Merck & Co.（MSD）
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Seagen
  • Shanghai Junshi Biosciences
  • Syndax Pharmaceuticals
  • Taiho Pharmaceutical
  • Tesaro（acquired by GSK）

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36505

Global Checkpoint Inhibitor Refractory Cancer Market to Reach US$48.8 Billion by 2030

The global market for Checkpoint Inhibitor Refractory Cancer estimated at US$31.5 Billion in the year 2024, is expected to reach US$48.8 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. PD-1 Inhibitor Type, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$33.0 Billion by the end of the analysis period. Growth in the PD-L1 Inhibitor Type segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.6 Billion While China is Forecast to Grow at 12.0% CAGR

The Checkpoint Inhibitor Refractory Cancer market in the U.S. is estimated at US$8.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.5 Billion by the year 2030 trailing a CAGR of 12.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Checkpoint Inhibitor Refractory Cancer Market - Key Trends & Drivers Summarized

Why Is Refractoriness to Checkpoint Inhibitors Emerging as a New Frontier in Oncology?

Checkpoint inhibitors revolutionized cancer treatment by unleashing the immune system to attack tumors, yet a significant proportion of patients show limited or no response-enter the complex landscape of checkpoint inhibitor refractory cancers. These are cancers that either do not initially respond to immune checkpoint blockade therapies (primary resistance) or that progress after a period of responsiveness (acquired resistance). This challenge is particularly acute in melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and triple-negative breast cancer, where resistance rates vary from 40% to over 60%, depending on tumor type and biomarker expression. Understanding the underlying causes of refractoriness is becoming a critical priority for oncologists, biopharma companies, and researchers alike. Tumor microenvironment dynamics, low tumor mutational burden, absence of T-cell infiltration (cold tumors), and immune escape mechanisms all play roles in reducing checkpoint efficacy. These insights are rapidly reshaping therapeutic development, driving innovations in combination therapies, novel immune targets, and personalized medicine approaches. With growing clinical demand for alternatives to monotherapy checkpoint blockade, the refractory cancer segment has moved from a clinical footnote to a central focus in the evolving immuno-oncology landscape.

Can Combination Therapies Offer a Breakthrough for Resistant Cancers?

Combination therapies are increasingly being seen as the most viable approach to overcoming checkpoint inhibitor resistance. These include pairings of checkpoint inhibitors with chemotherapy, radiation, targeted therapy, or other immunotherapies like oncolytic viruses, cancer vaccines, and T-cell agonists. Trials combining anti-PD-1/PD-L1 drugs with CTLA-4 inhibitors, such as ipilimumab, have shown improved response rates in specific subtypes of melanoma and NSCLC. Newer strategies are incorporating agents targeting LAG-3, TIGIT, and TIM-3-next-generation checkpoint molecules-to circumvent the limitations of first-generation drugs. Additionally, epigenetic modulators are being tested to reprogram “cold” tumors into “hot” ones by increasing T-cell infiltration, thereby making them more susceptible to checkpoint blockade. Personalized neoantigen vaccines and adoptive T-cell therapies, including CAR-T and TCR-T cells, are also under development to address tumor heterogeneity and immune evasion. While these strategies raise concerns around toxicity and cost, ongoing trials are optimizing dosing regimens and biomarker-based patient selection to improve efficacy and safety. The FDA and EMA are increasingly granting breakthrough designations and fast-track approvals to promising combo therapies, underscoring the urgency and potential of this therapeutic frontier.

What Role Are Diagnostics and Biomarkers Playing in Shaping Treatment Strategies?

Precision oncology is indispensable to addressing checkpoint inhibitor refractoriness, with companion diagnostics and biomarker profiling taking center stage. PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) status are foundational metrics, but newer biomarkers such as interferon-gamma signatures, T-cell receptor clonality, and gut microbiome composition are gaining traction. Advanced techniques like single-cell RNA sequencing and multiplex immunohistochemistry are helping researchers decode immune cell landscapes within tumors, enabling better prediction of resistance patterns. Circulating tumor DNA (ctDNA) analysis is becoming an essential tool in monitoring minimal residual disease and early relapse, particularly in the context of acquired resistance. Additionally, artificial intelligence is being used to integrate multi-omic data (genomic, transcriptomic, and proteomic) for real-time decision-making and patient stratification. These diagnostics are also aiding the selection of patients for emerging clinical trials, improving recruitment efficiency and trial outcomes. As reimbursement systems evolve to support personalized oncology, companion diagnostic development is closely tied to drug approvals, solidifying its role as a growth engine in the checkpoint inhibitor refractory cancer market.

What’s Driving Growth in the Market for Checkpoint Inhibitor Refractory Cancer Therapies?

The growth in the checkpoint inhibitor refractory cancer market is driven by several factors closely aligned with technological advances, clinical needs, and precision-based healthcare models. First, the expanding pool of patients receiving immunotherapies has naturally led to a parallel increase in refractory cases, creating a significant unmet need. Advances in next-generation sequencing and real-time molecular diagnostics are enabling more accurate identification of resistance mechanisms, thereby facilitating tailored treatment strategies. Pharmaceutical companies are accelerating investments in novel targets and immuno-oncology pipelines, spurred by promising trial data and regulatory incentives. From an end-use perspective, tertiary cancer care centers and academic hospitals are leading the adoption of advanced immunotherapeutic combinations, while decentralized access is improving via specialized oncology networks. Consumer behavior is also evolving-patients and caregivers are becoming more engaged in understanding treatment options, often seeking clinical trials or experimental therapies proactively. Moreover, growing availability of real-world evidence and patient registries is providing deeper insight into long-term treatment responses and resistance trends, enabling iterative innovation in drug development. These interconnected drivers are creating a dynamic ecosystem primed for growth, innovation, and improved outcomes in the battle against checkpoint inhibitor refractory cancers.

SCOPE OF STUDY:

The report analyzes the Checkpoint Inhibitor Refractory Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (PD-1 Inhibitor Type, PD-L1 Inhibitor Type, Other Types); Application (Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Celltrion
  • Genentech (Roche)
  • GlaxoSmithKline (GSK)
  • Hengrui Medicine
  • Incyte Corporation
  • Janssen Pharmaceuticals
  • Merck & Co. (MSD)
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Seagen
  • Shanghai Junshi Biosciences
  • Syndax Pharmaceuticals
  • Taiho Pharmaceutical
  • Tesaro (acquired by GSK)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Checkpoint Inhibitor Refractory Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Pipeline of Combination Therapies Spurs Innovation in Checkpoint Inhibitor Refractory Treatments
    • Advances in Biomarker Discovery Expand Addressable Population for Targeted Immunotherapies
    • Increasing Clinical Trial Activity Throws the Spotlight on Adaptive Immunotherapy Strategies
    • Regulatory Fast-Tracking of Oncology Drugs Accelerates Market Entry of New Refractory Cancer Therapies
    • Emergence of Personalized Cancer Vaccines Drives Research into Overcoming Immunotherapy Resistance
    • Rise of Next-Generation Immune Modulators Spurs Development of Post-Checkpoint Inhibitor Options
    • Advances in Genomic Sequencing Generate Insights into Resistance Mechanisms and New Targets
    • Increased Funding for Rare and Resistant Cancers Expands R&D Efforts in Refractory Segments
    • Real-World Evidence Generation Enhances Adoption of Refractory Cancer Treatment Protocols
    • Rising Incidence of Hard-to-Treat Cancers Drives Market Focus Toward Checkpoint Inhibitor Failures
    • Growing Demand for Cost-Effective Alternatives Spurs Development of Biosimilars in Oncology
    • Health Policy Support and Oncology Innovation Grants Sustain Market Growth for High-Risk Populations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Checkpoint Inhibitor Refractory Cancer Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Checkpoint Inhibitor Refractory Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for PD-1 Inhibitor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for PD-1 Inhibitor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for PD-1 Inhibitor Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for PD-L1 Inhibitor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for PD-L1 Inhibitor Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for PD-L1 Inhibitor Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lung Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Lung Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Bladder Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Bladder Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Bladder Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Melanoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Melanoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hodgkin Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hodgkin Lymphoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hodgkin Lymphoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • JAPAN
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • CHINA
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • EUROPE
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Checkpoint Inhibitor Refractory Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • FRANCE
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • GERMANY
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • INDIA
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030
  • AFRICA
    • Checkpoint Inhibitor Refractory Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Checkpoint Inhibitor Refractory Cancer by Type - PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Type - Percentage Breakdown of Value Sales for PD-1 Inhibitor Type, PD-L1 Inhibitor Type and Other Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Checkpoint Inhibitor Refractory Cancer by Application - Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Checkpoint Inhibitor Refractory Cancer by Application - Percentage Breakdown of Value Sales for Lung Cancer Application, Bladder Cancer Application, Melanoma Application, Hodgkin Lymphoma Application and Other Applications for the Years 2014, 2025 & 2030

IV. COMPETITION